

12<sup>th</sup> February, 2026

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Limited  
Exchange Plaza, C-1,  
Block- G, Bandra – Kurla Complex,  
Bandra (East), Mumbai – 400051  
**Symbol: AAKAAR**

Dear Sir/ Madam,

Ref.: Disclosure under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (“SEBI Regulations”)

Pursuant to Regulation 30(4)(i)(d) read with Schedule III of SEBI [Listing Obligations and Disclosure Requirements], Regulations 2015, we hereby submit the details as required under Para B, Clause 2(a) of Part A of Schedule III of the said Regulations of the SEBI Circular No. SEBI/HO/CFD/POD2/CIR/P/0155 dated November 11, 2024. This disclosure has been approved by our Board of Directors in their meeting held on 12.02.2026, at 11.30 a.m. [concluded at 12.45 p.m.]

The above details required under Regulation 30 of SEBI Listing regulations are provided in Annexure I to IV respectively.

Thanking you,

Yours truly,  
For Aakaar Medical Technologies Ltd.

Anoopkumar V. Pillai  
Company Secretary & Compliance Officer

Encl: as above.

### Annexure I

1	Name of the entity(ies) with whom agreement/JV is signed	Dermlite LLP, USA [which was acquired by FotoFinder Systems GmbH].
2	Area of Agreement/ JV	Authorised Dealer agreement for Territory – India.
3	Domestic/ International	International
4	Share exchange ratio/ JV ratio	Not applicable
5	Scope of Business operation of agreement/ JV	Exclusive distribution /marketing agreement for medical equipment and related accessories for DERMLITE Products.
6	Details of consideration paid/ received in agreement/ JV	Initial purchases to be paid prior to shipment of products. Subsequent payments to be decided mutually amongst parties.
7	Significant terms and conditions of agreement/ JV in brief	<ul style="list-style-type: none"> <li>Under this agreement, the company has exclusive rights in India to market Dermlite products in India as per commercial terms agreed between parties.</li> <li>The company expects meaningful revenue contribution from this agreement during the tenure of this agreement.</li> <li>In view of the confidentiality clause in the agreement, we are not permitted to share quantitative and other information pertaining to the agreement.</li> </ul>
8	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm's length”	No
9	Size of the entity(ies)	Not applicable
10	Rationale and benefit expected	By integrating FotoFinder and DermLite's diagnostic and AI-enabled imaging solutions, Aakaar intends to strengthen its end-to-end dermatology ecosystem, enhance clinical credibility, for sustained growth in the rapidly expanding medical aesthetics market
11	Any other information relevant to be shared	NA

## Annexure II

1	Name of the entity(ies) with whom agreement/JV is signed	Croma-Pharma GmbH, Austria
2	Area of Agreement/ JV	Distribution agreement for Territory – India.
3	Domestic/ International	International
4	Share exchange ratio/ JV ratio	Not applicable
5	Scope of Business operation of agreement/ JV	Exclusive distribution /marketing agreement for medical equipment - SAYPHA
6	Details of consideration paid/ received in agreement/ JV	Credit period as mutually agreed.
7	Significant terms and conditions of agreement/ JV in brief	<ul style="list-style-type: none"> <li>Under this agreement, the company has exclusive rights in India to market Croma-Pharma's medical equipment in India as per commercial terms agreed between parties.</li> <li>The company expects meaningful revenue contribution from this agreement during the tenure of this agreement.</li> <li>In view of the confidentiality clause in the agreement, we are not permitted to share quantitative and other information pertaining to the agreement.</li> </ul>
8	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No
9	Size of the entity(ies)	Not applicable
10	Rationale and benefit expected	The agreement strengthens the Company's dermatology and medical aesthetics portfolio, expected to enhance revenue visibility and expand its presence in high-growth premium segments.
11	Any other information relevant to be shared	NA

### Annexure III

1	Name of the entity(ies) with whom agreement/JV is signed	APS s.r.l [Italy] & Tricopat Global Sp. Z.o.o. [Poland]
2	Area of Agreement/ JV	Distribution agreement for Territory – India.
3	Domestic/ International	International
4	Share exchange ratio/ JV ratio	Not applicable
5	Scope of Business operation of agreement/ JV	Exclusive distribution /marketing MOU for medical device TRICOPAT
6	Details of consideration paid/ received in agreement/ JV	Advance payment for initial PO
7	Significant terms and conditions of agreement/ JV in brief	<ul style="list-style-type: none"> <li>Under this agreement, the company has exclusive rights in India to market TRICOPAT medical devices in India as per commercial terms agreed between parties.</li> <li>The company expects meaningful revenue contribution from this agreement during the tenure of this agreement.</li> <li>In view of the confidentiality clause in the agreement, we are not permitted to share quantitative and other information pertaining to the agreement.</li> </ul>
8	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	No
9	Size of the entity(ies)	Not applicable
10	Rationale and benefit expected	The agreement strengthens the Company's dermatology and medical aesthetics portfolio, expected to enhance revenue visibility and expand its presence in high-growth premium segments.
11	Any other information relevant to be shared	NA

**Annexure IV**

1	Name of the entity(ies) with whom agreement/JV is signed	TESS CO.LTD. / Zishel Medical, South Korea
2	Area of Agreement/ JV	Distribution agreement for Territory – India.
3	Domestic/ International	International
4	Share exchange ratio/ JV ratio	Not applicable
5	Scope of Business operation of agreement/ JV	Exclusive distribution /marketing agreement - XOMAGE Plant Exosomes
6	Details of consideration paid/ received in agreement/ JV	Advance payment
7	Significant terms and conditions of agreement/ JV in brief	<ul style="list-style-type: none"> <li>Under this agreement, the company has exclusive rights in India to market XOMAGE Plant Exosomes in India as per commercial terms agreed between parties.</li> <li>The company expects meaningful revenue contribution from this agreement during the tenure of this agreement.</li> <li>In view of the confidentiality clause in the agreement, we are not permitted to share quantitative and other information pertaining to the agreement.</li> </ul>
8	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm's length”	No
9	Size of the entity(ies)	Not applicable
10	Rationale and benefit expected	The agreement strengthens the Company's dermatology and medical aesthetics portfolio, expected to enhance revenue visibility and expand its presence in high-growth premium segments.
11	Any other information relevant to be shared	NA